Thermo Fisher Scientific Inc (NYSE: TMO)’s stock price has dropped by -2.22 in relation to previous closing price of 593.75. Nevertheless, the company has seen a loss of -0.64% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-31 that Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Is It Worth Investing in Thermo Fisher Scientific Inc (NYSE: TMO) Right Now?
The price-to-earnings ratio for Thermo Fisher Scientific Inc (NYSE: TMO) is above average at 35.13x. The 36-month beta value for TMO is also noteworthy at 0.77. There are mixed opinions on the stock, with 18 analysts rating it as a “buy,” 8 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for TMO is 381.88M, and at present, short sellers hold a 0.91% of that float. The average trading volume of TMO on February 05, 2025 was 2.01M shares.
TMO’s Market Performance
TMO’s stock has seen a -0.64% decrease for the week, with a 11.10% rise in the past month and a 6.27% gain in the past quarter. The volatility ratio for the week is 2.24%, and the volatility levels for the past 30 days are at 2.38% for Thermo Fisher Scientific Inc The simple moving average for the last 20 days is 2.14% for TMO’s stock, with a simple moving average of 1.70% for the last 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Bernstein repeating the rating for TMO by listing it as a “Outperform.” The predicted price for TMO in the upcoming period, according to Bernstein is $630 based on the research report published on January 10, 2025 of the current year 2025.
TMO Trading at 7.08% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.53% of loss for the given period.
Volatility was left at 2.38%, however, over the last 30 days, the volatility rate increased by 2.24%, as shares surge +9.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.03% upper at present.
During the last 5 trading sessions, TMO fell by -0.64%, which changed the moving average for the period of 200-days by +6.09% in comparison to the 20-day moving average, which settled at $568.39. In addition, Thermo Fisher Scientific Inc saw 11.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Williamson Stephen, who proposed sale 9,825 shares at the price of $585.59 back on Feb 04 ’25. After this action, Williamson Stephen now owns shares of Thermo Fisher Scientific Inc, valued at $5,753,422 using the latest closing price.
Pettiti Gianluca, the Officer of Thermo Fisher Scientific Inc, proposed sale 300 shares at $585.59 during a trade that took place back on Feb 04 ’25, which means that Pettiti Gianluca is holding shares at $175,677 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.13, with 6.45 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is 9.69.
Currently, EBITDA for the company is 7.34 billion with net debt to EBITDA at 2.61. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The receivables turnover for the company is 5.23for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.66.
Conclusion
In summary, Thermo Fisher Scientific Inc (TMO) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
